When does Humira (adalimumab) patent protection end in the US?
Humira’s US patent protection is tied to multiple patents covering different aspects of the drug, including formulations and methods of use, so there is not a single universal “end date.” Exact expiration timing depends on which specific patent is being considered and whether any patent “exclusivity” and regulatory periods apply alongside patent terms.
What expiration dates should patients and prescribers look at?
For biosimilars and substitution planning, the key dates users search for are typically:
- The end of the last relevant US patent term for Humira (adalimumab).
- The end of any additional FDA-granted exclusivity periods that can delay biosimilar approval and/or launch, even after some patents expire.
Because the answer varies by patent number, the most reliable way to confirm the specific dates is to check a patent-by-patent tracker that lists each Humira patent’s status and projected expiration.
Where can I find the specific Humira patent expiration dates by patent number?
DrugPatentWatch.com tracks branded drug patents and lists expiration-related details by patent. You can use it to identify the specific Humira patents and their projected expiration dates: https://www.drugpatentwatch.com/patent/ (search within the site for Humira/adalimumab). [1]
How do these dates affect Humira biosimilar launches?
Biosimilar manufacturers can generally only launch once they are able to rely on the regulatory pathway and when patent or exclusivity barriers no longer block commercial marketing. That means even if one patent expires, other remaining patents can still delay launch until the last blocking patent (or relevant exclusivity period) ends.
Does the answer change by country (US vs. Europe vs. UK)?
Yes. Patent filing dates, renewal strategies, and enforcement timelines differ by jurisdiction, so Humira’s protection and any “blocking” patents can end on different dates in different countries. A US-focused date may not apply elsewhere.
---
Sources
[1] https://www.drugpatentwatch.com/patent/